Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan...
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers.
Target Price
The average target price of IDIA.SW is 5.2 and suggests 37% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell